APA (7th ed.) Citation

G, F., S, S., A, P., F, H., G, L., L, M., . . . TM, J. (2009). Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS (London, England), 23(16), 2115. https://doi.org/10.1097/QAD.0b013e32832fef5b

Chicago Style (17th ed.) Citation

G, Fätkenheuer, Staszewski S, Plettenburg A, Hackman F, Layton G, McFadyen L, Davis J, and Jenkins TM. "Activity, Pharmacokinetics and Safety of Lersivirine (UK-453,061), a Next-generation Nonnucleoside Reverse Transcriptase Inhibitor, During 7-day Monotherapy in HIV-1-infected Patients." AIDS (London, England) 23, no. 16 (2009): 2115. https://doi.org/10.1097/QAD.0b013e32832fef5b.

MLA (9th ed.) Citation

G, Fätkenheuer, et al. "Activity, Pharmacokinetics and Safety of Lersivirine (UK-453,061), a Next-generation Nonnucleoside Reverse Transcriptase Inhibitor, During 7-day Monotherapy in HIV-1-infected Patients." AIDS (London, England), vol. 23, no. 16, 2009, p. 2115, https://doi.org/10.1097/QAD.0b013e32832fef5b.